> Pharmaceutical Litigation > Pradaxa: Uncontrollable Bleeding
Pradaxa, a blood thinner that contains the active ingredient dabigatran etexilate mesylate, has been linked to an alarming number of adverse events in patients involving serious and uncontrollable bleeding. Pradaxa is used to reduce the risk of stroke and blood clots in people with atrial fibrillation. Those suffering from this condition, in which part of the heart does not beat as it should, are at an increased risk of stroke due to blood clots. Pradaxa lowers that risk by preventing the formation of blood clots that can cause stroke. But it can also be dangerous.
Because Pradaxa prevents blood clots, it carries with it the risk of serious bleeding and hemorrhaging. This risk is particularly high in patients with low kidney function, which allows dangerous levels of the drug to build up in the system. Despite this, many patients with undetermined kidney function are placed on the drug.
The nonprofit Institute for Safe Medication Practices released a report in May 2012 estimating that there were 542 deaths associated with Pradaxa in 2011. Between its approval in 2010 and the release of the report in 2011, 817 reports had been received by the Food and Drug Administration of injuries from Pradaxa. According to those numbers, Pradaxa patients are 5 times more likely to bleed to death than patients taking the alternative blood thinner warfarin.
Another alarming truth about Pradaxa is that, unlike warfarin, there is no antidote to the blood-thinning effects and thus no way to stop the bleeding.
Bleeding and kidney malfunction are life-threatening. If you were injured or lost a loved one because of the adverse effects of Pradaxa, contact the attorneys at the Law Offices of Brian D. Witzer. They are dedicated to seeking justice and compensation for your suffering.
Contact us today by calling (888) WITZER-6 for a free, no-obligation consultation.